These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

196 related articles for article (PubMed ID: 16956306)

  • 1. Intravenous ibandronate: in the treatment of osteoporosis.
    Croom KF; Scott LJ
    Drugs; 2006; 66(12):1593-601; discussion 1602-3. PubMed ID: 16956306
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of daily and intermittent use of ibandronate on bone mass and bone turnover in postmenopausal osteoporosis: a review of three phase II studies.
    Schimmer RC; Bauss F
    Clin Ther; 2003 Jan; 25(1):19-34. PubMed ID: 12637110
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and tolerability of intravenous ibandronate injections in postmenopausal osteoporosis: 2-year results from the DIVA study.
    Eisman JA; Civitelli R; Adami S; Czerwinski E; Recknor C; Prince R; Reginster JY; Zaidi M; Felsenberg D; Hughes C; Mairon N; Masanauskaite D; Reid DM; Delmas PD; Recker RR
    J Rheumatol; 2008 Mar; 35(3):488-97. PubMed ID: 18260172
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Intravenous ibandronate injections in postmenopausal women with osteoporosis: one-year results from the dosing intravenous administration study.
    Delmas PD; Adami S; Strugala C; Stakkestad JA; Reginster JY; Felsenberg D; Christiansen C; Civitelli R; Drezner MK; Recker RR; Bolognese M; Hughes C; Masanauskaite D; Ward P; Sambrook P; Reid DM
    Arthritis Rheum; 2006 Jun; 54(6):1838-46. PubMed ID: 16729277
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and safety of ibandronate given by intravenous injection once every 3 months.
    Adami S; Felsenberg D; Christiansen C; Robinson J; Lorenc RS; Mahoney P; Coutant K; Schimmer RC; Delmas PD
    Bone; 2004 May; 34(5):881-9. PubMed ID: 15121020
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Monthly oral ibandronate therapy in postmenopausal osteoporosis: 1-year results from the MOBILE study.
    Miller PD; McClung MR; Macovei L; Stakkestad JA; Luckey M; Bonvoisin B; Reginster JY; Recker RR; Hughes C; Lewiecki EM; Felsenberg D; Delmas PD; Kendler DL; Bolognese MA; Mairon N; Cooper C
    J Bone Miner Res; 2005 Aug; 20(8):1315-22. PubMed ID: 16007327
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Once-monthly ibandronate for postmenopausal osteoporosis: review of a new dosing regimen.
    Pyon EY
    Clin Ther; 2006 Apr; 28(4):475-90. PubMed ID: 16750461
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of oral ibandronate administered daily or intermittently on fracture risk in postmenopausal osteoporosis.
    Chesnut CH; Skag A; Christiansen C; Recker R; Stakkestad JA; Hoiseth A; Felsenberg D; Huss H; Gilbride J; Schimmer RC; Delmas PD;
    J Bone Miner Res; 2004 Aug; 19(8):1241-9. PubMed ID: 15231010
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and tolerability of once-monthly oral ibandronate (150 mg) and once-weekly oral alendronate (70 mg): additional results from the Monthly Oral Therapy With Ibandronate For Osteoporosis Intervention (MOTION) study.
    Emkey R; Delmas PD; Bolognese M; Borges JL; Cosman F; Ragi-Eis S; Recknor C; Zerbini CA; Neate C; Sedarati F; Epstein S
    Clin Ther; 2009 Apr; 31(4):751-61. PubMed ID: 19446148
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Oral daily ibandronate prevents bone loss in early postmenopausal women without osteoporosis.
    McClung MR; Wasnich RD; Recker R; Cauley JA; Chesnut CH; Ensrud KE; Burdeska A; Mills T;
    J Bone Miner Res; 2004 Jan; 19(1):11-8. PubMed ID: 14753731
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Beyond daily dosing: clinical experience.
    Cooper C
    Bone; 2006 Apr; 38(4 Suppl 1):S13-7. PubMed ID: 16520105
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Intravenous ibandronate injections given every three months: a new treatment option to prevent bone loss in postmenopausal women.
    Stakkestad JA; Benevolenskaya LI; Stepan JJ; Skag A; Nordby A; Oefjord E; Burdeska A; Jonkanski I; Mahoney P;
    Ann Rheum Dis; 2003 Oct; 62(10):969-75. PubMed ID: 12972476
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Three monthly intravenous injections of ibandronate in the treatment of postmenopausal osteoporosis.
    Thiébaud D; Burckhardt P; Kriegbaum H; Huss H; Mulder H; Juttmann JR; Schöter KH
    Am J Med; 1997 Oct; 103(4):298-307. PubMed ID: 9382122
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Once-monthly dosing: an effective step forward.
    Reid DM
    Bone; 2006 Apr; 38(4 Suppl 1):S18-22. PubMed ID: 16533625
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Oral and intravenous ibandronate in the management of postmenopausal osteoporosis: a comprehensive review.
    Reginster JY
    Curr Pharm Des; 2005; 11(28):3711-28. PubMed ID: 16305506
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Long-term administration of quarterly IV ibandronate is effective and well tolerated in postmenopausal osteoporosis: 5-year data from the DIVA study long-term extension.
    Bianchi G; Czerwinski E; Kenwright A; Burdeska A; Recker RR; Felsenberg D
    Osteoporos Int; 2012 Jun; 23(6):1769-78. PubMed ID: 21975558
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Once-monthly oral ibandronate in postmenopausal osteoporosis: translation and updated review.
    Rossini M; Viapiana O; Gatti D; Adami S
    Clin Ther; 2009 Jul; 31(7):1497-510. PubMed ID: 19695399
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Insufficiently dosed intravenous ibandronate injections are associated with suboptimal antifracture efficacy in postmenopausal osteoporosis.
    Recker R; Stakkestad JA; Chesnut CH; Christiansen C; Skag A; Hoiseth A; Ettinger M; Mahoney P; Schimmer RC; Delmas PD
    Bone; 2004 May; 34(5):890-9. PubMed ID: 15121021
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and tolerability of once-monthly oral ibandronate in postmenopausal osteoporosis: 2 year results from the MOBILE study.
    Reginster JY; Adami S; Lakatos P; Greenwald M; Stepan JJ; Silverman SL; Christiansen C; Rowell L; Mairon N; Bonvoisin B; Drezner MK; Emkey R; Felsenberg D; Cooper C; Delmas PD; Miller PD
    Ann Rheum Dis; 2006 May; 65(5):654-61. PubMed ID: 16339289
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The effect on bone mass and bone markers of different doses of ibandronate: a new bisphosphonate for prevention and treatment of postmenopausal osteoporosis: a 1-year, randomized, double-blind, placebo-controlled dose-finding study.
    Ravn P; Clemmesen B; Riis BJ; Christiansen C
    Bone; 1996 Nov; 19(5):527-33. PubMed ID: 8922653
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.